Physician profile
Gerald B Hogsette
NPI 1437122850
$562.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2021: $40.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $104.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.92 | 2019 | |
| Allergan, INC. | $47.06 | 2019 | |
| Medela LLC | $40.17 | 2021 | |
| Abbott Laboratories | $30.48 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.55 | 2019 | |
| Shire North American Group INC | $13.92 | 2019 | |
| Merck Sharp & Dohme LLC | $13.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 | |
| Pfizer INC. | $12.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.97 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Hogsette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.